New FDA-cleared PTSD treatment reports 68% remission in clinical trial
⏮ BeforePTSD patients have had limited options that target brain activity this precisely.
✅ NowA newly FDA-cleared treatment uses personalized brain mapping and magnetic stimulation for PTSD.
In short
- The FDA has cleared a PTSD treatment that uses personalized brain mapping and magnetic stimulation.
- In a clinical trial, symptoms fell by 52% and 68% of patients reached remission.
- Researchers say the approach could lead to more precise treatments for other mental health conditions.
Why the Good News Desk likes this one
The treatment combines personalized brain mapping with magnetic stimulation to target the activity linked to PTSD. The trial results reported a 52% symptom reduction and 68% remission. Researchers believe the method could also shape care for other mental health conditions.
Advertisement
From ScienceDaily
A newly FDA-cleared PTSD treatment uses personalized brain mapping and magnetic stimulation to target abnormal brain activity, with a clinical trial reporting a 52% reduction in symptoms and 68% remission. Researchers believe the technology could transform PTSD care and pave the way for more precise treatments for other mental health conditions.
Ask this story
More like this
Advertisement